One of two men convicted in the first of several trials stemming from a 2014 standoff led by renegade rancher Cliven Bundy against federal authorities in Nevada was sentenced on Wednesday to 68 years in prison for his role in the armed confrontation. Gregory Burleson, 53, of Phoenix, was found guilty in April of eight felony counts, including charges of threatening and assaulting federal officers, obstruction of justice, interstate travel in aid of extortion and firearms offenses related to a crime of violence. The uprising at Bundy's ranch near Bunkerville, Nevada, 75 miles (120 km) northeast of Las Vegas, grew out of a dispute in which federal agents seized Bundy's cattle over his refusal to pay fees required for grazing his livestock on government land.
By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline's new chief executive announced plans on Wednesday to narrow the focus of the group's drug research by ditching more than 30 drug projects to improve returns in its core pharmaceuticals business. Emma Walmsley, who took over in April, said GSK would in future allocate 80 percent of its R&D budget to respiratory and HIV/infectious diseases, along with two other potential areas of oncology and immuno-inflammation.
One of two men convicted in the first of several trials stemming from a 2014 standoff led by renegade rancher Cliven Bundy against federal authorities in Nevada was sentenced on Wednesday to 68 years in prison for his role in the armed confrontation. Gregory Burleson, 53, of Phoenix, was found guilty in April of eight felony counts, including charges of threatening and assaulting federal officers, obstruction of justice, interstate travel in aid of extortion and firearms offenses related to a crime of violence. The uprising at Bundy's ranch near Bunkerville, Nevada, 75 miles (120 km) northeast of Las Vegas, grew out of a dispute in which federal agents seized Bundy's cattle over his refusal to pay fees required for grazing his livestock on government land.
By Ben Hirschler LONDON (Reuters) - GlaxoSmithKline's new chief executive announced plans on Wednesday to narrow the focus of the group's drug research by ditching more than 30 drug projects to improve returns in its core pharmaceuticals business. Emma Walmsley, who took over in April, said GSK would in future allocate 80 percent of its R&D budget to respiratory and HIV/infectious diseases, along with two other potential areas of oncology and immuno-inflammation.
No comments:
Post a Comment